The efficacy and tolerability of fluticasone propionate aqueous nasal spray in children with seasonal allergic rhinitis

摘要: Fluticasone propionate aqueous nasal spray (FPANS) contains fluticasone propionate, which is a new topically active glucocorticoid with approximately twice the potency of belcomethasone dipropionate. In this European multicentre study, 143 children seasonal allergic rhinitis were recruited: 47 received FPANS 100 micrograms once day (od), 46 200 od, and 50 patients placebo for 4 weeks. Treatment efficacy was assessed using diary card symptom scores sneezing, rhinorrhoea, blockage itching, eye watering/irritation. Patients receiving or demonstrated statistically significant improvements in median all symptoms recorded, when compared placebo. There no differences between groups improvement scores. effect on watering/irritation could be attributed to either Use rescue antihistamine medication significantly reduced group The adverse events profile similar three treatment groups, reported generally mild related patients' rhinitis.